Breaking Silos In Drug Development: The Power Of An Integrated Model

Experts discuss how Altasciences leverages its fully integrated Preclinical-to-Clinical development model to streamline the transition from nonclinical research to first-in-human studies. By unifying preclinical services, clinical pharmacology, bioanalysis, manufacturing, and project management within a single organization, Altasciences minimizes the operational silos and communication gaps that often slow traditional development pathways. This integrated structure reduces the number of vendor handoffs, enhances continuity across teams, and enables faster, more informed decision-making throughout the development process.

With shared systems, centralized oversight, and collaborative scientific expertise, sponsors benefit from improved data continuity, greater operational efficiency, and a more cohesive development strategy from study design through clinical execution. The model also allows teams to proactively identify risks, adapt quickly to emerging data, and maintain momentum during critical transition points between development phases. As timelines become increasingly compressed in early drug development, Altasciences’ integrated approach helps sponsors accelerate progress toward first-in-human trials while maintaining quality, consistency, and regulatory readiness.